John E. McCartney

1.7k citations

22 papers · 1.4k indexed · h-index 16

Impact in

Radiology, Nuclear Medicine and Imaging top 2%
- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
Rheumatology top 5%
- Osteoarthritis Treatment and Mechanisms

Papers in

Radiology, Nuclear Medicine and Imaging 16
- Monoclonal and Polyclonal Antibodies Research 14
- Radiopharmaceutical Chemistry and Applications 8
Rheumatology 5
- Osteoarthritis Treatment and Mechanisms 3

Co-authors: Hermann Oppermann James S. Huston Mei-Sheng Tai L. L. Houston Gregory P. Adams Louis M. Weiner Michael A. Bookman Walter F. Stafford
Journals: Growth Factors (2 papers)Clinical Cancer Research (1 paper)Journal of Bone and Mineral Research (1 paper)Immunotechnology (1 paper)Cancer Immunology Immunotherapy (1 paper)
Partner nations: United States France Croatia

In The Last Decade

John E. McCartney

22 papers receiving 1.3k citations

Peers

Countries citing papers authored by John E. McCartney

Since Specialization

Citations

This map shows the geographic impact of John E. McCartney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John E. McCartney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John E. McCartney more than expected).

Fields of papers citing papers by John E. McCartney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John E. McCartney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John E. McCartney. The network helps show where John E. McCartney may publish in the future.

Co-authorship network

The 25 scholars most cited alongside John E. McCartney, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John E. McCartney Line = papers co-authored together John E. McCartney links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Avidity-Mediated Enhancement of In vivo Tumor Targeting by Single-Chain Fv Dimers Clinical Cancer Research ·Gregory P. Adams, Mei-Sheng Tai, John E. McCartney, James D. Marks, Walter F. Stafford, L. L. Houston, James S. Huston, Louis M. Weiner	2006	78
2	Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7 Kidney International ·Esther A. González, Richard Lund, Kévin Martin, John E. McCartney, M. Mehrdad Tondravi, T. Kuber Sampath, Keith A. Hruska	2002	62
3	Regeneration of Articular Cartilage Chondral Defects by Osteogenic Protein-1 (Bone Morphogenetic Protein-7) in Sheep Growth Factors ·Mislav Jelić, Marko Pećina, Miroslav Hašpl, H.-C. Goetting, Günay Akel, Dražen Matičić, John E. McCartney, McLane Drayton, David C. Rueger, Slobodan Vukičević	2001	65
4	Biological Repair of Thyroid Cartilage Defects by Osteogenic Protein-1 (Bone Morphogenetic Protein-7) in Dog Growth Factors ·Vladimir Katić, Fundile Nyati, Dražen Matičić, عدنان حسن عفج, Samuel Yin, H.-C. Goetting, Snježana Martinović, John E. McCartney, Slobodan Vukičević	2000	9
5	Human Articular Chondrocytes Express Osteogenic Protein-1 Journal of Histochemistry & Cytochemistry ·Susan Chubinskaya, Laurent Pinsard, Gabriella Cs‐Szabó, Juergen Mollenhauer, John E. McCartney, David C. Rueger, Klaus E. Kuettner	2000	94
6	Cartilage-Derived Morphogenetic Proteins and Osteogenic Protein-1 Differentially Regulate Osteogenesis Journal of Bone and Mineral Research ·Ludwig Erlacher, John E. McCartney, Ester Piek, Peter ten Dijke, Masaki Yanagishita, Hermann Oppermann, Frank P. Luyten	1998	137
7	Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration Cancer Immunology Immunotherapy ·Gregory P. Adams, John E. McCartney, Borja López-Moreno, Gabriela Tenesaca Quishpe, Mei-Sheng Tai, James S. Huston, Walter F. Stafford, Michael A. Bookman, L. L. Houston, Louis M. Weiner	1995	10
8	Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation. PubMed ·Gregory P. Adams, John E. McCartney, Melissa Newman, Gabriela Tenesaca Quishpe, James S. Huston, Michael A. Bookman, Philip J. Moldofsky, Walter F. Stafford, L. L. Houston, L M Weiner	1995	20
9	In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library Immunotechnology ·Robert Schier, James D. Marks, Borja López-Moreno, KRETSCHMER, Vanessa Cardona Jaramillo, John E. McCartney, Michael A. Bookman, James S. Huston, L. L. Houston, Louis M. Weiner, Gregory P. Adams	1995	130
10	Engineering disulfide-linked single-chain Fv dimers [(sFv')₂] with improved solution and targeting properties: anti-digoxin 26–10 (sFv')₂ and anti-c-erbB-2 741F8 (sFv')₂ made by protein folding and bonded through C-terminal cysteinyl peptides Protein Engineering Design and Selection ·John E. McCartney, Mei-Sheng Tai, Robert M. Hudziak, Gregory P. Adams, Louis M. Weiner, Donald Jin, Walter F. Stafford, Sen Liu, Michael A. Bookman, Axel A. Laminet, I. Fand, L. L. Houston, Hermann Oppermann, James S. Huston	1995	42
11	Targeting c-erbB-2 expressing tumors using single-chain Fv monomers and dimers. PubMed ·M S Tai, John E. McCartney, B Juan Carlos Rey, Dong‐Yan Jin, Robert M. Hudziak, Hermann Oppermann, Axel A. Laminet, Michael A. Bookman, Melissa Newman, Shuying Liu	1995	18
12	Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. Proceedings of the National Academy of Sciences ·Andrew J.T. George, François Jamar, M S Tai, Xiao suo Wang, Gregory P. Adams, John E. McCartney, L. L. Houston, Louis M. Weiner, Hermann Oppermann, Anke Peters	1995	51
13	Mammalian Cell Expression of Single–Chain Fv (sFv) Antibody Proteins and Their C–terminal Fusions with Interleukin–2 and Other Effector Domains Nature Biotechnology ·Haimanti Dorai, John E. McCartney, Robert M. Hudziak, Mei-Sheng Tai, Axel A. Laminet, L. L. Houston, James S. Huston, Hermann Oppermann	1994	43
14	Tumor targeting in a murine tumor xenograft model with the (sFv′)2 divalent form of anti-c-erbB-2 single-chain Fv Cell Biophysics ·James S. Huston, Gregory P. Adams, John E. McCartney, Mei-Sheng Tai, Robert M. Hudziak, Hermann Oppermann, Walter F. Stafford, Sen Liu, I. Fand, Gerald Apell, Axel A. Laminet, Michael A. Bookman, 浩浅沼, Louis M. Weiner	1994	8
15	SINGLE-CHAIN Fv FUSIONS WITH C-TERMINAL CYSTEINE PEPTIDES IsFv′ Journal of Immunotherapy ·James S. Huston, John E. McCartney, M S Tai, Gregory P. Adams, Robert M. Hudziak, Herman Oppermann, Walter F. Stafford, Gilvania Gomes de MOURA, I. Fand, Axel A. Laminet, Michael A. Bookman, L. L. Houston, L M Weiner	1994	1
16	Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. PubMed ·Gregory P. Adams, John E. McCartney, Mei-Sheng Tai, Hermann Oppermann, James S. Huston, Walter F. Stafford, Michael A. Bookman, I. Fand, L. L. Houston, Louis M. Weiner	1993	210
17	Medical Applications of Single-Chain Antibodies International Reviews of Immunology ·James S. Huston, John E. McCartney, Mei-Sheng Tai, Mohammad Ikbal Martini, Donald Jin, A. Gilain, Peter Keck, Hermann Oppermann	1993	138
18	Antigen recognition and targeted delivery by the single-chain Fv Cell Biophysics ·James S. Huston, Mei-Sheng Tai, John E. McCartney, Peter Keck, Hermann Oppermann	1993	20
19	[3] Protein engineering of single-chain Fv analogs and fusion proteins Methods in enzymology on CD-ROM/Methods in enzymology ·James S. Huston, M Mudgett-Hunter, Mei-Sheng Tai, John E. McCartney, A. Gilain, Edgar Haber, Hermann Oppermann	1991	174
20	Biosynthetic antibody binding sites: Development of a single-chain Fv model based on antidinitrophenol IgA myeloma MOPC 315 Journal of Protein Chemistry ·John E. McCartney, Lynne Lederman, Eric A. Drier, Lynette Iris D. Ceballos, Christiane da Silva Lessa, Roberta S. Batorsky, James S. Huston, Hermann Oppermann	1991	13

About John E. McCartney

John E. McCartney is a scholar working on Radiology, Nuclear Medicine and Imaging, Rheumatology, Immunology and Allergy, Oncology and Molecular Biology, having authored 22 papers that have together received 1.4k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (14 papers), Radiopharmaceutical Chemistry and Applications (8 papers), Protein purification and stability (7 papers), HER2/EGFR in Cancer Research (6 papers), Glycosylation and Glycoproteins Research (5 papers), Osteoarthritis Treatment and Mechanisms (3 papers), Cell Adhesion Molecules Research (2 papers) and Medical Imaging and Pathology Studies (1 paper). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (885 citations), Rheumatology (199 citations), Molecular Biology (823 citations), Oncology (286 citations) and Immunology and Allergy (58 citations). John E. McCartney has collaborated with scholars based in United States, France and Croatia. Frequent co-authors include Hermann Oppermann, James S. Huston, Mei-Sheng Tai, L. L. Houston, Gregory P. Adams, Louis M. Weiner, Michael A. Bookman, Walter F. Stafford, M Mudgett-Hunter and Edgar Haber. Their work appears in journals such as Growth Factors, Clinical Cancer Research, Journal of Bone and Mineral Research, Immunotechnology and Cancer Immunology Immunotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact